{"id":2009,"date":"2025-12-06T18:13:00","date_gmt":"2025-12-06T22:13:00","guid":{"rendered":"https:\/\/sites.nd.edu\/pdnano\/?p=2009"},"modified":"2025-12-18T18:19:41","modified_gmt":"2025-12-18T22:19:41","slug":"precision-chemotherapy-externally-controlled-nanocarriers-for-aggressive-cancers","status":"publish","type":"post","link":"https:\/\/sites.nd.edu\/pdnano\/?p=2009","title":{"rendered":"Precision Chemotherapy: Externally Controlled Nanocarriers for Aggressive Cancers"},"content":{"rendered":"<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-full is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"899\" height=\"757\" src=\"https:\/\/sites.nd.edu\/pdnano\/files\/2025\/12\/image-7.png\" alt=\"\" class=\"wp-image-2010\" style=\"width:450px\" srcset=\"https:\/\/sites.nd.edu\/pdnano\/files\/2025\/12\/image-7.png 899w, https:\/\/sites.nd.edu\/pdnano\/files\/2025\/12\/image-7-300x253.png 300w, https:\/\/sites.nd.edu\/pdnano\/files\/2025\/12\/image-7-768x647.png 768w\" sizes=\"auto, (max-width: 899px) 100vw, 899px\" \/><\/figure>\n<\/div>\n\n\n<p>Aggressive malignancies like <strong>triple-negative breast cancer (TNBC)<\/strong>, ovarian cancer, and prostate cancer remain difficult to treat because they often lack the surface receptors required for traditional targeted therapies. <sup><\/sup><sup><\/sup><sup><\/sup><sup><\/sup>Standard treatments like doxorubicin (Dox) are effective at killing cancer but cause severe systemic side effects, most notably cardiotoxicity. <sup><\/sup><sup><\/sup><sup><\/sup><sup><\/sup>To overcome these barriers, the Nallathamby Lab at Notre Dame has developed a &#8220;receptor-independent&#8221; delivery system that uses external magnetic fields to control chemotherapy with pinpoint precision. <sup><\/sup><sup><\/sup><sup><\/sup><sup><\/sup><\/p>\n\n\n\n<h4 class=\"wp-block-heading\">The Innovation: Magnetoelectric &#8220;On-Demand&#8221; Release<\/h4>\n\n\n\n<p>The team\u2019s platform utilizes <strong>Magnetoelectric Silica Nanoparticles (MagSiNs)<\/strong>. <sup><\/sup>These tiny carriers, averaging just 6.7 nanometers in diameter, consist of a magnetic cobalt ferrite core encapsulated in a thin piezoelectric silica shell. <sup><\/sup><sup><\/sup><sup><\/sup><sup><\/sup><sup><\/sup><sup><\/sup><sup><\/sup><sup><\/sup><sup><\/sup><\/p>\n\n\n\n<p>This unique structure allows for dual-mode control:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Guidance:<\/strong> Static magnetic fields can be used to concentrate the nanoparticles specifically at the tumor site. <\/li>\n\n\n\n<li><strong>Triggered Delivery:<\/strong> When exposed to a low-frequency alternating magnetic field, the nanoparticles undergo a charge polarization that triggers the release of the drug payload directly inside the cancer cell. <\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">Breakthrough Results in Aggressive Cancer Models<\/h4>\n\n\n\n<p>The study tested Dox-loaded MagSiNs across multiple cancer cell lines, including those derived from women of African descent, to address TNBC subtypes that are often more resistant to treatment. <\/p>\n\n\n\n<p>Key findings include:<\/p>\n\n\n\n<p><strong>Superior Efficacy:<\/strong> In aggressive HCC1500 breast cancer cells, the MagSiN system reduced cell viability to <strong>14%<\/strong>, compared to <strong>42%<\/strong> when treated with the same dose of free doxorubicin. <\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Enhanced Safety:<\/strong> The platform demonstrated high selectivity, effectively killing cancer cells while sparing healthy endothelial cells (HUVECs), which maintained high viability compared to those exposed to free drug. <\/li>\n\n\n\n<li><strong>Defined Mechanisms:<\/strong> Mechanistic studies confirmed that the particles are internalized through <strong>dynamin-dependent endocytosis<\/strong> and accumulate in the cell&#8217;s lysosomes before the drug is released. <\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">The Future of Theragnostics<\/h4>\n\n\n\n<p>Because MagSiNs are magnetic, they offer a clear path toward <strong>theragnostics<\/strong>\u2014the combination of therapy and diagnostics. <sup><\/sup><sup><\/sup><sup><\/sup><sup><\/sup><sup><\/sup>Future clinical applications could involve using <strong>MRI<\/strong> to visualize a patient&#8217;s tumor and precisely trigger drug release simultaneously, minimizing off-target exposure to healthy organs like the heart and liver. <sup><\/sup><sup><\/sup><sup><\/sup><sup><\/sup><sup><\/sup><sup><\/sup><sup><\/sup><sup><\/sup><sup><\/sup><\/p>\n\n\n\n<p>This research highlights the potential of externally actuated, label-free strategies to overcome the limitations of traditional targeted medicine. <sup><\/sup><\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\" \/>\n\n\n\n<p><strong>Project Team:<\/strong> Jichong Lyu, Aurelie Brownsberger, Carlie Kudary, Margo Waters, and Prakash D. Nallathamby. <sup><\/sup><strong>Support:<\/strong> This work was supported by the <strong>Berthiaume Institute for Precision Health (BIPH)<\/strong>, <strong>NDnano<\/strong>, and the <strong>CDMRP-PRCRP IDEA award<\/strong>. <sup><\/sup><sup><\/sup><sup><\/sup><sup><\/sup><\/p>\n\n\n\n<p><a href=\"https:\/\/chemrxiv.org\/engage\/chemrxiv\/article-details\/692a9bb2a10c9f5ca1502481\">https:\/\/chemrxiv.org\/engage\/chemrxiv\/article-details\/692a9bb2a10c9f5ca1502481<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Aggressive malignancies like triple-negative breast cancer (TNBC), ovarian cancer, and prostate cancer remain difficult to treat because they often lack the surface receptors required for traditional targeted therapies. Standard treatments like doxorubicin (Dox) are effective at killing cancer but cause severe systemic side effects, most notably cardiotoxicity. To overcome these barriers, the Nallathamby Lab at &hellip; <\/p>\n<p><a class=\"more-link block-button\" href=\"https:\/\/sites.nd.edu\/pdnano\/?p=2009\">Continue reading &raquo;<\/a><\/p>\n","protected":false},"author":2672,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2009","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Precision Chemotherapy: Externally Controlled Nanocarriers for Aggressive Cancers - Nallathamby Laboratory<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/sites.nd.edu\/pdnano\/?p=2009\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Precision Chemotherapy: Externally Controlled Nanocarriers for Aggressive Cancers - Nallathamby Laboratory\" \/>\n<meta property=\"og:description\" content=\"Aggressive malignancies like triple-negative breast cancer (TNBC), ovarian cancer, and prostate cancer remain difficult to treat because they often lack the surface receptors required for traditional targeted therapies. Standard treatments like doxorubicin (Dox) are effective at killing cancer but cause severe systemic side effects, most notably cardiotoxicity. To overcome these barriers, the Nallathamby Lab at &hellip; Continue reading &raquo;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/sites.nd.edu\/pdnano\/?p=2009\" \/>\n<meta property=\"og:site_name\" content=\"Nallathamby Laboratory\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/prakashdn\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-06T22:13:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-18T22:19:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/sites.nd.edu\/pdnano\/files\/2025\/12\/image-7.png\" \/>\n\t<meta property=\"og:image:width\" content=\"899\" \/>\n\t<meta property=\"og:image:height\" content=\"757\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Prakash\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@prakashdn\" \/>\n<meta name=\"twitter:site\" content=\"@prakashdn\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Prakash\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/sites.nd.edu\\\/pdnano\\\/?p=2009#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/sites.nd.edu\\\/pdnano\\\/?p=2009\"},\"author\":{\"name\":\"Prakash\",\"@id\":\"https:\\\/\\\/sites.nd.edu\\\/pdnano\\\/#\\\/schema\\\/person\\\/3bec2d9fbd957b23abd53a0a5445b4f0\"},\"headline\":\"Precision Chemotherapy: Externally Controlled Nanocarriers for Aggressive Cancers\",\"datePublished\":\"2025-12-06T22:13:00+00:00\",\"dateModified\":\"2025-12-18T22:19:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/sites.nd.edu\\\/pdnano\\\/?p=2009\"},\"wordCount\":401,\"image\":{\"@id\":\"https:\\\/\\\/sites.nd.edu\\\/pdnano\\\/?p=2009#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/sites.nd.edu\\\/pdnano\\\/files\\\/2025\\\/12\\\/image-7.png\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/sites.nd.edu\\\/pdnano\\\/?p=2009\",\"url\":\"https:\\\/\\\/sites.nd.edu\\\/pdnano\\\/?p=2009\",\"name\":\"Precision Chemotherapy: Externally Controlled Nanocarriers for Aggressive Cancers - Nallathamby Laboratory\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/sites.nd.edu\\\/pdnano\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/sites.nd.edu\\\/pdnano\\\/?p=2009#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/sites.nd.edu\\\/pdnano\\\/?p=2009#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/sites.nd.edu\\\/pdnano\\\/files\\\/2025\\\/12\\\/image-7.png\",\"datePublished\":\"2025-12-06T22:13:00+00:00\",\"dateModified\":\"2025-12-18T22:19:41+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/sites.nd.edu\\\/pdnano\\\/#\\\/schema\\\/person\\\/3bec2d9fbd957b23abd53a0a5445b4f0\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/sites.nd.edu\\\/pdnano\\\/?p=2009#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/sites.nd.edu\\\/pdnano\\\/?p=2009\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/sites.nd.edu\\\/pdnano\\\/?p=2009#primaryimage\",\"url\":\"https:\\\/\\\/sites.nd.edu\\\/pdnano\\\/files\\\/2025\\\/12\\\/image-7.png\",\"contentUrl\":\"https:\\\/\\\/sites.nd.edu\\\/pdnano\\\/files\\\/2025\\\/12\\\/image-7.png\",\"width\":899,\"height\":757},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/sites.nd.edu\\\/pdnano\\\/?p=2009#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/sites.nd.edu\\\/pdnano\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Precision Chemotherapy: Externally Controlled Nanocarriers for Aggressive Cancers\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/sites.nd.edu\\\/pdnano\\\/#website\",\"url\":\"https:\\\/\\\/sites.nd.edu\\\/pdnano\\\/\",\"name\":\"Modular Nanotechnologies and Nanomaterials\",\"description\":\"Modular and scalable nanotechnology for imaging, sensing and therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/sites.nd.edu\\\/pdnano\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/sites.nd.edu\\\/pdnano\\\/#\\\/schema\\\/person\\\/3bec2d9fbd957b23abd53a0a5445b4f0\",\"name\":\"Prakash\",\"url\":\"https:\\\/\\\/sites.nd.edu\\\/pdnano\\\/?author=2672\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Precision Chemotherapy: Externally Controlled Nanocarriers for Aggressive Cancers - Nallathamby Laboratory","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/sites.nd.edu\/pdnano\/?p=2009","og_locale":"en_US","og_type":"article","og_title":"Precision Chemotherapy: Externally Controlled Nanocarriers for Aggressive Cancers - Nallathamby Laboratory","og_description":"Aggressive malignancies like triple-negative breast cancer (TNBC), ovarian cancer, and prostate cancer remain difficult to treat because they often lack the surface receptors required for traditional targeted therapies. Standard treatments like doxorubicin (Dox) are effective at killing cancer but cause severe systemic side effects, most notably cardiotoxicity. To overcome these barriers, the Nallathamby Lab at &hellip; Continue reading &raquo;","og_url":"https:\/\/sites.nd.edu\/pdnano\/?p=2009","og_site_name":"Nallathamby Laboratory","article_publisher":"https:\/\/www.facebook.com\/prakashdn","article_published_time":"2025-12-06T22:13:00+00:00","article_modified_time":"2025-12-18T22:19:41+00:00","og_image":[{"width":899,"height":757,"url":"https:\/\/sites.nd.edu\/pdnano\/files\/2025\/12\/image-7.png","type":"image\/png"}],"author":"Prakash","twitter_card":"summary_large_image","twitter_creator":"@prakashdn","twitter_site":"@prakashdn","twitter_misc":{"Written by":"Prakash","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/sites.nd.edu\/pdnano\/?p=2009#article","isPartOf":{"@id":"https:\/\/sites.nd.edu\/pdnano\/?p=2009"},"author":{"name":"Prakash","@id":"https:\/\/sites.nd.edu\/pdnano\/#\/schema\/person\/3bec2d9fbd957b23abd53a0a5445b4f0"},"headline":"Precision Chemotherapy: Externally Controlled Nanocarriers for Aggressive Cancers","datePublished":"2025-12-06T22:13:00+00:00","dateModified":"2025-12-18T22:19:41+00:00","mainEntityOfPage":{"@id":"https:\/\/sites.nd.edu\/pdnano\/?p=2009"},"wordCount":401,"image":{"@id":"https:\/\/sites.nd.edu\/pdnano\/?p=2009#primaryimage"},"thumbnailUrl":"https:\/\/sites.nd.edu\/pdnano\/files\/2025\/12\/image-7.png","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/sites.nd.edu\/pdnano\/?p=2009","url":"https:\/\/sites.nd.edu\/pdnano\/?p=2009","name":"Precision Chemotherapy: Externally Controlled Nanocarriers for Aggressive Cancers - Nallathamby Laboratory","isPartOf":{"@id":"https:\/\/sites.nd.edu\/pdnano\/#website"},"primaryImageOfPage":{"@id":"https:\/\/sites.nd.edu\/pdnano\/?p=2009#primaryimage"},"image":{"@id":"https:\/\/sites.nd.edu\/pdnano\/?p=2009#primaryimage"},"thumbnailUrl":"https:\/\/sites.nd.edu\/pdnano\/files\/2025\/12\/image-7.png","datePublished":"2025-12-06T22:13:00+00:00","dateModified":"2025-12-18T22:19:41+00:00","author":{"@id":"https:\/\/sites.nd.edu\/pdnano\/#\/schema\/person\/3bec2d9fbd957b23abd53a0a5445b4f0"},"breadcrumb":{"@id":"https:\/\/sites.nd.edu\/pdnano\/?p=2009#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/sites.nd.edu\/pdnano\/?p=2009"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/sites.nd.edu\/pdnano\/?p=2009#primaryimage","url":"https:\/\/sites.nd.edu\/pdnano\/files\/2025\/12\/image-7.png","contentUrl":"https:\/\/sites.nd.edu\/pdnano\/files\/2025\/12\/image-7.png","width":899,"height":757},{"@type":"BreadcrumbList","@id":"https:\/\/sites.nd.edu\/pdnano\/?p=2009#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/sites.nd.edu\/pdnano\/"},{"@type":"ListItem","position":2,"name":"Precision Chemotherapy: Externally Controlled Nanocarriers for Aggressive Cancers"}]},{"@type":"WebSite","@id":"https:\/\/sites.nd.edu\/pdnano\/#website","url":"https:\/\/sites.nd.edu\/pdnano\/","name":"Modular Nanotechnologies and Nanomaterials","description":"Modular and scalable nanotechnology for imaging, sensing and therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/sites.nd.edu\/pdnano\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/sites.nd.edu\/pdnano\/#\/schema\/person\/3bec2d9fbd957b23abd53a0a5445b4f0","name":"Prakash","url":"https:\/\/sites.nd.edu\/pdnano\/?author=2672"}]}},"_links":{"self":[{"href":"https:\/\/sites.nd.edu\/pdnano\/index.php?rest_route=\/wp\/v2\/posts\/2009","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sites.nd.edu\/pdnano\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sites.nd.edu\/pdnano\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sites.nd.edu\/pdnano\/index.php?rest_route=\/wp\/v2\/users\/2672"}],"replies":[{"embeddable":true,"href":"https:\/\/sites.nd.edu\/pdnano\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2009"}],"version-history":[{"count":1,"href":"https:\/\/sites.nd.edu\/pdnano\/index.php?rest_route=\/wp\/v2\/posts\/2009\/revisions"}],"predecessor-version":[{"id":2011,"href":"https:\/\/sites.nd.edu\/pdnano\/index.php?rest_route=\/wp\/v2\/posts\/2009\/revisions\/2011"}],"wp:attachment":[{"href":"https:\/\/sites.nd.edu\/pdnano\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2009"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sites.nd.edu\/pdnano\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2009"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sites.nd.edu\/pdnano\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2009"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}